Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07290036 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
A Phase 1 study of Psoriatic Arthritis and Axial Spondyloarthritis, sponsored by UCB Biopharma SRL.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 392
- Enrollment target
- 18
- Study locations
NCT07290036: Recruiting Phase 1 study of Psoriatic Arthritis and Axial Spondyloarthritis, sponsored by UCB Biopharma SRL.
NCT07290036 is a Phase 1 study of Psoriatic Arthritis and Axial Spondyloarthritis that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 392 participants, below the 845-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (54% lower). The trial reports 18 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07290036, a Phase 1 study of Psoriatic Arthritis and Axial Spondyloarthritis, is actively recruiting participants, sponsored by UCB Biopharma SRL.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 392 participants
- Enrollment target
- 18
- Study locations
Study Summary
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
Primary Outcome
Steady-state trough concentration (Ctrough,ss) will be reported.
Conditions Studied
Interventions
- DRUG Bimekizumab regimen 1 iv
- DRUG Bimekizumab regimen 2 iv
- DRUG Bimekizumab regimen 3 sc
Study Locations (18)
California
- Pa0019 127 - Apple Valley
- Pa0019 111 - Covina
- Pa0019 117 - Riverside
- Pa0019 125 - San Leandro
- Pa0019 126 - Temecula
- Pa0019 120 - Whittier
- Pa0019 128 - Whittier
Texas
- Pa0019 136 - Colleyville
- Pa0019 124 - Plano
Arizona
- Pa0019 114 - Peoria
Colorado
- Pa0019 123 - Fort Collins
Florida
- Pa0019 113 - South Miami
Michigan
- Pa0019 134 - Lansing
New Mexico
- Pa0019 131 - Albuquerque
Pennsylvania
- Pa0019 115 - Duncansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2025-12-10 |
| Est. Completion | 2028-07-04 |
| Phase | Phase 1 |
What NCT07290036 shows while recruiting
NCT07290036 is an interventional study that assigns participants to a tested intervention. The registered 392 participants enrollment target is mid-sized for trials with a published cap, below the 845-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (54% lower).
The record links to 2 conditions, with Psoriatic Arthritis appearing as the primary indexed condition, and to 3 interventions - of which Bimekizumab regimen 1 iv is the first listed.
NCT07290036 lists 18 locations in 11 states (California, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT07290036 about?
NCT07290036 is a clinical study titled "A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults". To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
What is the current status of trial NCT07290036?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 392 participants. The study started on 2025-12-10. Estimated completion is 2028-07-04.
What conditions does trial NCT07290036 study?
This clinical trial studies the following conditions: Psoriatic Arthritis, Axial Spondyloarthritis.
What interventions are being tested in trial NCT07290036?
The interventions under investigation include: Bimekizumab regimen 1 iv (DRUG), Bimekizumab regimen 2 iv (DRUG), Bimekizumab regimen 3 sc (DRUG).
Who is sponsoring clinical trial NCT07290036?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07290036 being conducted?
This trial has 18 study locations across Arizona, California, Colorado, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07290036's enrollment target sits among peer trials
392 20th of 48 higher than 29 of 48 other Psoriatic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
COMPLETED · Phase 1
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Rheumatology Diet Study
RECRUITING
-
Stronger Together Psoriatic Arthritis Wellness Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06397703 · 392 participants · Phase 2
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
- NCT06625775 · 392 participants · Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- NCT07220967 · 392 participants · Phase 4
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
- NCT05640999 · 393 participants · Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI